Arctic Bioscience

Arctic Bioscience leverages over 30 years of expertise in marine extracts to develop novel ingredients from herring roe, targeting the nutraceutical and pharmaceutical markets. Its mission is centered on providing effective and healthy therapies for people with autoimmune disorders using its proprietary marine membrane lipid technology. The company has established the 'Romega' brand for its nutraceutical products and maintains a strong commitment to sustainability and scientific validation. While currently private and likely pre-revenue from its pharmaceutical pipeline, it represents a specialized player in the marine bioactives space.

Proprietary platform for extracting and formulating bioactive marine membrane lipids, specifically high-DHA Omega-3 phospholipids, from Norwegian herring roe for nutraceutical and pharmaceutical applications.

Faces competition from large, established Omega-3 ingredient suppliers (e.g., DSM, BASF) and krill oil companies in the nutraceutical space, and from major biopharma firms with advanced autoimmune pipelines in the pharmaceutical arena. Differentiation is based on its specialized herring roe phospholipid platform, sustainable Norwegian sourcing, and dual commercial/R&D capabilities.